Advertisement

Methods for Analysis of Nanoparticle Immunosuppressive Properties In Vitro and In Vivo

  • Timothy M. Potter
  • Barry W. Neun
  • Marina A. DobrovolskaiaEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1682)

Abstract

Adverse drug effects on the immune system function represent a significant concern in the pharmaceutical industry, because 10–20% of the drug withdrawal from the market is accounted to immunotoxicity. Immunosuppression is one such adverse effect. The traditional immune function test used to estimate materials’ immunosuppression is a T-cell-dependent antibody response (TDAR). This method involves a 28 day in vivo study evaluating the animal’s antibody titer to a known antigen (KLH) with and without challenge. Due to the limited quantities of novel drug candidates, an in vitro method called human leukocyte activation (HuLa) assay has been developed to substitute the traditional TDAR assay during early preclinical development. In this test, leukocytes isolated from healthy donors vaccinated with the current year’s flu vaccine are incubated with Fluzone in the presence or absence of a test material. The antigen-specific leukocyte proliferation is then measured by ELISA analyzing incorporation of BrdU into DNA of the proliferating cells. Here, we describe the experimental procedures for investigating immunosuppressive properties of nanoparticles by both TDAR and HuLa assays, discuss the in vitro–in vivo correlation of these methods, and show a case study using the iron oxide nanoparticle formulation, Feraheme.

Key words

Nanoparticles Immunosuppression Leukocyte proliferation Antigen TDAR 

Notes

Acknowledgment

This project has been funded in whole or in part by federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

References

  1. 1.
    Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 6(11):904–916. doi: 10.1038/nrd2423 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Smith DA, Schmid EF (2006) Drug withdrawals and the lessons within. Curr Opin Drug Discov Devel 9(1):38–46PubMedGoogle Scholar
  3. 3.
    Wysowski DK, Nourjah P (2004) Analyzing prescription drugs as causes of death on death certificates. Public Health Rep 119(6):520. doi: 10.1016/j.phr.2004.09.001 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Wysowski DK, Swartz L (2005) Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 165(12):1363–1369. doi: 10.1001/archinte.165.12.1363 CrossRefPubMedGoogle Scholar
  5. 5.
    Tyner K, Sadrieh N (2011) Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. Methods Mol Biol 697:17–31. doi: 10.1007/978-1-60327-198-1_3 CrossRefPubMedGoogle Scholar
  6. 6.
    Tyner KM, Zou P, Yang X, Zhang H, Cruz CN, Lee SL (2015) Product quality for nanomaterials: current U.S. experience and perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 7(5):640–654. doi: 10.1002/wnan.1338 CrossRefPubMedGoogle Scholar
  7. 7.
    Bancos S, Tyner K, Weaver JL (2013) Immunotoxicity testing for drug–nanoparticle conjugates: regulatory considerations. In: Dobrovolskaia MA, SE MN (eds) Handbook of immunological properties of engineered nanomaterials. World Scientific Publishing, SingaporeGoogle Scholar
  8. 8.
    Dobrovolskaia MA, Germolec DR, Weaver JL (2009) Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol 4(7):411–414. doi: 10.1038/nnano.2009.175 CrossRefPubMedGoogle Scholar
  9. 9.
    Collinge M, Cole SH, Schneider PA, Donovan CB, Kamperschroer C, Kawabata TT (2010) Human lymphocyte activation assay: an in vitro method for predictive immunotoxicity testing. J Immunotoxicol 7(4):357–366. doi: 10.3109/1547691x.2010.523881 CrossRefPubMedGoogle Scholar
  10. 10.
    Shen CC, Liang HJ, Wang CC, Liao MH, Jan TR (2011) A role of cellular glutathione in the differential effects of iron oxide nanoparticles on antigen-specific T cell cytokine expression. Int J Nanomedicine 6:2791–2798. doi: 10.2147/ijn.s25588 PubMedPubMedCentralGoogle Scholar
  11. 11.
    Shen CC, Liang HJ, Wang CC, Liao MH, Jan TR (2012) Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity. Int J Nanomedicine 7:2729–2737. doi: 10.2147/ijn.s31054 PubMedPubMedCentralGoogle Scholar
  12. 12.
    Shen CC, Wang CC, Liao MH, Jan TR (2011) A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice. Int J Nanomedicine 6:1229–1235. doi: 10.2147/ijn.s21019 PubMedPubMedCentralGoogle Scholar
  13. 13.
    Dobrovolskaia MA, McNeil SE (2013) Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release 172(2):456–466. doi: 10.1016/j.jconrel.2013.05.025 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2018

Authors and Affiliations

  • Timothy M. Potter
    • 1
  • Barry W. Neun
    • 1
  • Marina A. Dobrovolskaia
    • 1
    Email author
  1. 1.Cancer Research Technology Program, Nanotechnology Characterization LaboratoryLeidos Biomedical Research, Inc., Frederick National Laboratory for Cancer ResearchFrederickUSA

Personalised recommendations